In this first segment of a one-on-one interview, a part of the Oncology Stakeholders Summit, Spring 2015 series, Michael Kolodziej, MD, and Bruce Feinberg, DO, address some of the key issues payers face as they make coverage decisions on the new PD-1 drug class of immuno-oncology agents.
Dr Kolodziej, national medical director of oncology strategy for Aetna, points out that prescribing behavior has thus far reflected the indications tested during the clinical trial process and, to a lesser extent, where National Comprehensive Cancer Network (NCCN) places them in the treatment guidelines for melanoma and now non-small cell lung cancer. Similarly, payers’ coverage policies reflect approved labeling and the NCCN recommendations.
If they reach their fullest potential, PD-1 inhibitors may be used to target up to 30 different tumor types, says Dr Feinberg, vice president and chief medical officer of Cardinal Health Specialty Solutions. They both agree that a key challenge to successful treatment outcomes with PD-1 inhibitors and for appropriate coverage decision making will be overcoming the lack of biomarkers to determine who will most benefit with these agents.
Dr Feinberg emphasizes that the FDA labeling and NCCN recommendations restrict use of PD-1 agents to patients who have suffered relapses. He believes that the excitement over this drug class, on both the provider and patient levels, will drive the use of these agents earlier in treatment.
The problem, according to Dr Kolodziej, is that clinical evidence on the optimal use of PD-1 inhibitors may lag behind actual use. Such new drug classes, he thinks, may require reconsideration of the way evidence is collected to help not only informed patient care but also coverage policy.
Watch our related Peer Exchange, Oncology Stakeholders Summit, Spring 2015.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More